13 Most Oversold Healthcare Stocks So Far in 2025

Page 9 of 11

3. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Relative Strength Index (RSI): 30.42 

Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics, continues to advance its product portfolio and market presence in 2025.

A key growth driver is its droplet digital PCR (ddPCR) platform, led by the QX600 system. The company recently acquired Stilla Technologies to enhance ddPCR capabilities and enter new molecular testing markets. New instrument launches, including the QX Series dd instruments and QX Continuum, are simplifying workflows and offering greater flexibility, with mid-single-digit revenue growth expected in 2025.

Despite being listed among the most oversold stocks, Bio-Rad Laboratories, Inc. (NYSE:BIO) also launched several products to strengthen its diagnostics and research offerings. These include the EZ-Check Salmonella spp. Kit, approved by AOAC International, StarBright dyes for spectral flow cytometry, and the XP-Design Assay Salmonella Serotyping solution, which provides rapid and accurate food safety testing.

In bioprocess chromatography, the corporation expanded its offerings with Nuvia wPrime 2A media for scalable biomolecule purification and extended Foresight Pro prepacked columns for GMP-ready biotherapeutic production. These innovations support both small- and large-scale research and manufacturing workflows.

While challenges remain in the U.S. academic and government sectors, Bio-Rad Laboratories, Inc. (NYSE:BIO) is seeing improved performance in international markets, including Japan and Korea. At the Wells Fargo Healthcare Conference in September 2025, the company highlighted strong Q2 results driven by chromatography and consumables, with a capital markets day planned for spring 2026 to outline further growth strategies.

Page 9 of 11